Data Sheet (Cat.No.T3547)

TargetMol

Sotagliflozin

Chemical Properties



CAS No. : 1018899-04-1

Formula: C21H25ClO5S

Molecular Weight: 424.94

Storage: Keep away from moisture,Keep away from direct sunlight
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Sotagliflozin (LP-802034) is an orally bioavailable inhibitor of the sodium-glucose co-transporter subtype 1 (SGLT1) and 2 (SGLT2), with potential antihyperglycemic activity.
Targets(IC50)	SGLT
In vitro	LX4211 inhibits [14C]AMG uptake with IC50 of 62.0 nM for mouse SGLT1 and 0.6 nM for mouse SGLT2, respectively. [2]
In vivo	In mice, LX4211 (60 mg/kg, p.o.) reduces intestinal glucose absorption by inhibiting SGLT1, resulting in net increases in GLP-1 and PYY release and decreases in GIP release and blood glucose excursions. [2] In nonobese diabetes-prone mice with type 1 diabetes, Sotagliflozin (30 mg/kg) significantly improves glycemic control, without increasing the rate of hypoglycemia measurements. [3]

Solubility Information

Solubility	DMSO: 262.5 mg/mL (617.73 mM),Sonication is recommended. H2O: < 1 mg/mL (insoluble or slightly soluble), Ethanol: 14 mg/mL (32.95 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.3533 mL	11.7664 mL	23.5327 mL
5 mM	0.4707 mL	2.3533 mL	4.7065 mL
10 mM	0.2353 mL	1.1766 mL	2.3533 mL
50 mM	0.0471 mL	0.2353 mL	0.4707 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Zambrowicz B, et al. Clin Pharmacol Ther. 2012, 92(2), 158-169.
Ding L, Chen X, Zhang W, et al.Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling.The Journal of Clinical Investigation.2023, 133(1).
Powell DR, et al. J Pharmacol Exp Ther. 2013, 345(2), 250-259.
Powell DR, et al. Diabetes Metab Syndr Obes. 2015, 8, 121-187.